Cardiovascular

Novo expands Wegovy’s US label to reduce cardiovascular events

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Wegovy (semaglutide) as a treatment to reduce the risk…

Novo Nordisk signs $1.46bn deal to develop molecular glue therapies

Novo Nordisk has signed a collaboration and licensing agreement with US-based biotech Neomorph to discover and develop multiple molecular glue…

United Therapeutics sues FDA over handling of Liquidia’s NDA

United Therapeutics has sued the US Food and Drug Administration (FDA), claiming the agency did not follow rules when approving…

CSL’s ‘big’ post-heart attack drug fails in Phase III trial

Australian CSL has released topline results from the Phase III AEGIS-II trial of CSL112 in patients following an acute myocardial…

Silence announces $120m private placement for depositary shares

Silence Therapeutics has announced an oversubscribed private placement of its 5,714,286 American depositary shares (ADS) priced at $21 each. The…

BridgeBio secures $1.25bn for genetic therapy development

BridgeBio Pharma has secured strategic financing of $1.25bn from Blue Owl Capital and the Canada Pension Plan Investment Board (CPP…

Comanche raises $75m to develop preeclampsia therapy

US-based Comanche Biopharma has raised $75m in an oversubscribed Series B financing round to develop its small interfering RNA (siRNA)…

Windtree and Lee’s sign licence deal for heart failure therapy

Windtree Therapeutics and Lee's Pharmaceutical have signed a licence agreement to develop and market the former’s istaroxime for acute heart…

BridgeBio gears up for FDA review of acoramidis following Phase III results

BridgeBio Pharma has published results from the Phase III ATTRibute-CM trial evaluating acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).…

Avidity and BMS enter $2.3bn deal for cardiovascular targets

Avidity Biosciences has entered an international licencing and research partnership with Bristol Myers Squibb (BMS) to discover, develop and market cardiovascular targets…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close